Rizwan Qazi, MD
Nephrology · Las Vegas, NVNPI 1407073273
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,207 of the $2,699 with a category attached, or 81.8%. 18 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 29.1% of the total. Reporting peaked in 2020 at $725 and has fallen 68.8% since, to $226 in 2025.
Across 50 payments — averaging $53.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$785
- Amgen$679
- Nxstage Medical, Inc.$202
- Travere Therapeutics, Inc.$161
- GSK$139
- Aurinia Pharma U.S., Inc.$125
- plus $608 from 12 others
What the payments were for
- Travel & lodging$49218%
- Food & beverage$2,20782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 11 | $785 |
| Amgen | 14 | $679 |
| Nxstage Medical, Inc. | 2 | $202 |
| Travere Therapeutics, Inc. | 2 | $161 |
| GSK | 2 | $139 |
| Aurinia Pharma U.S., Inc. | 1 | $125 |
| Boston Scientific | 1 | $125 |
| Fisher Scientific Company L.L.C. | 1 | $120 |
| Sanofi-aventis U.S. LLC | 1 | $90 |
| Akebia Therapeutics Inc | 2 | $51 |
| AstraZeneca | 3 | $45 |
| Cormedix Inc. | 2 | $40 |
| Calliditas Therapeutics US Inc. | 2 | $40 |
| Bayer | 2 | $40 |
| Vifor Pharma, Inc. | 1 | $17 |
| Argon Medical Devices, Inc. | 1 | $15 |
| Medtronic | 1 | $13 |
| Covidien LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Parsabiv$238
- Watchman$125
- Filspari$125
- BENLYSTA$122
- KRYSTEXXA$120
- BRAHMS PCT KRYPTOR$120
- COVERA$120
- NXSTAGE SYSTEM ONE$104
How this compares
$2,699 in reported general payments places this provider in the 60th percentile of 125 nephrology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProsolParenteral Amino Acid 20% No.1 | 23 | $7,300 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Las Vegas
- Samuel KantorLas Vegas$319K
- Richard CottieroLas Vegas$220K
- Mark VishnepolskyLas Vegas$68K
- Baishali NairLas Vegas$12K
- Gene OngLas Vegas$11K
- Jeffrey RyuLas Vegas$9K
- Luana PillonLas Vegas$9K
- Lawrence LehrnerLas Vegas$8K
- Hassan OsmanLas Vegas$8K
- Marwan TakieddineLas Vegas$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.